Time to Rethink Biomarkers in Heart Failure

Prof. Dr. R.A. de Boer
Department of Cardiology, University Medical Center Groningen
The Netherlands

Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preserved ejection fraction (HFpEF). Prof. De Boer’s research focuses on novel genes involved in cardiac remodeling, fibrosis, and metabolic changes and diabetes. He will critically discuss the value of different biomarkers in heart failure, including HFpEF.

Wednesday, 28.06.2017
12:00 – 13:00h
Bibliothek at DHZB
Augustenburger Platz 1, Berlin